Mert Karaca
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mert Karaca has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Haluk Barbaros Oral
Department of Immunology, Faculty of Medicine, Bursa Uludağ University, 16059 Bursa, Türkiye
4 shared publications - Digdem Yoyen-Ermis
Bursa Uludağ Üniversitesi Tıp Fakültesi, İmmünoloji Anabilim Dalı, Bursa
2 shared publications - Esra Uzaslan
Department of Pulmonary Medicine, Bursa Uludağ University Medical School, Bursa, Türkiye
2 shared publications - Abdülmecit Yildiz
Bursa Uludağ University, Faculty of Medicine, Department of Internal Medicine, Division of Nephrology, Bursa, Türkiye
1 shared publication - Ahmet Ursavaş
Bursa Uludağ Üniversitesi Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Bursa, Türkiye
1 shared publication - Ahmet Yurttaş
Alanya Alaaddin Keykubat University, Faculty of Medicine, Department of Pulmonology, Alanya, Antalya, Türkiye
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by Uludag Universitesi Tip Fakultesi Dergisi in Uludağ Üniversitesi Tıp Fakültesi Dergisi
- Vol. 52
Association Between Panel-reactive Antibody Positivity and Platelet Indices in Kidney Transplant Candidates
Panel-reactive antibody (PRA) is an established marker of pre-transplant immunological sensitization; however, the relationship between PRA positivity and routinely measured platelet indices remains unclear. The present retrospective observational study investigated the association between PRA positivity and platelet count, as well as indices, in adult kidney transplant candidates. Following the screening of 450 candidates, 208 were deemed eligible after excluding patients with active infection, those using medications affecting platelet indices, or those for whom simultaneous PRA and complete blood count measurements were unavailable. The demographic, laboratory, and immunological data of all participants were recorded. Of these, 58 (27.9%) were classified as PRA-positive (PRA >10%) and 150 (72.1%) as PRA-negative (PRA ≤10%). The cohort comprised 114 women (54.8%) and 94 men (45.2%). Compared with PRA-negative patients, PRA-positive patients had a higher proportion of women (77.6% vs. 46.0%; p < 0.001), longer median dialysis duration (51.5 [28.5–85.0] vs. 26.0 [2.75–50.25] months; p < 0.001), and higher median platelet distribution width (PDW; 16.45 [16.07–16.90] vs. 16.20 [15.80–16.60] fL; p = 0.006). However, platelet count, mean platelet volume, and plateletcrit were comparable. In multivariable analysis, female sex, longer dialysis duration, peritoneal dialysis, and higher PDW values were independently associated with PRA positivity, although the absolute difference between the PRA-positive and PRA-negative groups was small (16.45 vs. 16.20 fL). Higher PDW was associated with PRA positivity in kidney transplant candidates; however, the small between-group difference and the observational design preclude conclusions regarding its clinical utility. Further prospective studies are required to confirm this association.
- 22 October 2026
- Published by Uludag Universitesi Tip Fakultesi Dergisi in Uludağ Üniversitesi Tıp Fakültesi Dergisi
- Vol. 52
Open AccessAssociation Between Panel-reactive Antibody Positivity and Platelet Indices in Kidney Transplant Candidates
Panel-reactive antibody (PRA) is an established marker of pre-transplant immunological sensitization; however, the relationship between PRA positivity and routinely measured platelet indices remains unclear. The present retrospective observational study investigated the association between PRA positivity and platelet count, as well as indices, in adult kidney transplant candidates. Following the screening of 450 candidates, 208 were deemed eligible after excluding patients with active infection, those using medications affecting platelet indices, or those for whom simultaneous PRA and complete blood count measurements were unavailable. The demographic, laboratory, and immunological data of all participants were recorded. Of these, 58 (27.9%) were classified as PRA-positive (PRA >10%) and 150 (72.1%) as PRA-negative (PRA ≤10%). The cohort comprised 114 women (54.8%) and 94 men (45.2%). Compared with PRA-negative patients, PRA-positive patients had a higher proportion of women (77.6% vs. 46.0%; p < 0.001), longer median dialysis duration (51.5 [28.5–85.0] vs. 26.0 [2.75–50.25] months; p < 0.001), and higher median platelet distribution width (PDW; 16.45 [16.07–16.90] vs. 16.20 [15.80–16.60] fL; p = 0.006). However, platelet count, mean platelet volume, and plateletcrit were comparable. In multivariable analysis, female sex, longer dialysis duration, peritoneal dialysis, and higher PDW values were independently associated with PRA positivity, although the absolute difference between the PRA-positive and PRA-negative groups was small (16.45 vs. 16.20 fL). Higher PDW was associated with PRA positivity in kidney transplant candidates; however, the small between-group difference and the observational design preclude conclusions regarding its clinical utility. Further prospective studies are required to confirm this association.
- Open Access
- 29 April 2025
- Published by Doc Design and Informatics Co. Ltd. in Turkish Journal of Immunology
- p. 2-21
PANoptosis: A Coordinated Response in the Diversity of Cell Death
- 29 April 2025
- Published by Doc Design and Informatics Co. Ltd. in Turkish Journal of Immunology
- p. 2-21
Open AccessPANoptosis: A Coordinated Response in the Diversity of Cell Death
- 20 April 2025
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 59 (2) , 174-190
SARS-CoV-2 Enfeksiyonunda Hastalık Şiddetine Göre İndolamin 2,3-Dioksijenaz Enziminin İncelenmesi
Kinürenin yolağı, yol boyunca oluşan metabolitler ve enzimler aracılığıyla neredeyse tüm bağışıklık tepkileriyle etkileşime girmektedir. Hız sınırlayıcı enzim olan indolamin 2,3-dioksijenaz (IDO), yolağın başlangıç adımında oksidoredüktaz olarak görev yapmakta olup triptofanın kinürenine dönüşümünü katalizler ve çeşitli enfeksiyöz hastalıkların patogeneziyle ilişkilendirilmiştir. Bu çalışmada, koronavirüs hastalığı 2019 [coronavirus diseases-2019 (COVID-19)] hastalarının serum IDO-1 düzeyleri, Th1-2- 17 ile ilişkili sitokinlerin düzeyleri ve hematolojik parametreler, hastalığın şiddeti (hafif, orta, şiddetli) göz önünde bulundurularak araştırılması amaçlanmıştır. Yüz otuz hasta ve 91 sağlıklı kontrol için IDO1 serum seviyeleri enzim ilişkili immünsorban assay [enzyme linked immunosorbant assay (ELISA)] yöntemi kullanılarak ölçülmüş ve karşılaştırılmıştır. IDO gen lokusundaki daha önce enflamasyonla ilişkilendirilmiş olan tek nükleotit polimorfizm [single nucleotid polymorphism (SNP)] bölgesi taranmıştır. SNP analizleri, erime eğrisi (melting curve) analiziyle gerçekleştirilmiştir. Kırk COVID-19 hastasının IDO-1 intronik varyant rs7820268 ve IDO-2 inaktivitesinden sorumlu rs4503083 SNP bölgeleri, elli iki sağlıklı kontrol ile karşılaştırmalı olarak incelenmiştir. Tüm sonuçlar istatistiksel olarak analiz edilmiş ve karşılaştırılmıştır. IDO-1 serum konsantrasyonları hasta grubunda sağlıklı kontrol grubuna göre anlamlı olarak düşük bulunmuştur (p< 0.0001). Ayrıca, şiddetli hasta grubundaki IDO-1 serum seviyeleri, hafif hasta grubundan daha düşük olarak belirlenmiştir (p= 0.026). Hasta grubunda IL-4, IL-6, IL-10, TNF-α serum seviyeleri anlamlı derecede yüksek bulunurken, IFN-γ seviyeleri düşük olarak tespit edilmiştir. IDO1 ve IL-6 seviyeleri arasında ise negatif bir korelasyon bulunmuştur (r= -0.3503, p= 0.0391). Hastalık şiddetine göre sınıflandırılan hasta gruplarında lenfosit, monosit, nötrofil ve akut faz reaktan değerleri karşılaştırıldığında anlamlı farklılıklar bulunmuştur. SNP analizi sonucunda, rs7820268 IDO-1 bölgesi için CC genotipi COVID-19 hasta grubunda sağlıklı kontrol grubuna göre önemli ölçüde daha yüksek bulunmuştur (p= 0.0017). Bu veriler, IDO-1 rs7820268 SNP bölgesindeki polimorfizmin COVID-19'a duyarlılıkla ilişkili olabileceğini düşündürmektedir.
- 20 April 2025
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 59 (2) , 174-190
SARS-CoV-2 Enfeksiyonunda Hastalık Şiddetine Göre İndolamin 2,3-Dioksijenaz Enziminin İncelenmesi
Kinürenin yolağı, yol boyunca oluşan metabolitler ve enzimler aracılığıyla neredeyse tüm bağışıklık tepkileriyle etkileşime girmektedir. Hız sınırlayıcı enzim olan indolamin 2,3-dioksijenaz (IDO), yolağın başlangıç adımında oksidoredüktaz olarak görev yapmakta olup triptofanın kinürenine dönüşümünü katalizler ve çeşitli enfeksiyöz hastalıkların patogeneziyle ilişkilendirilmiştir. Bu çalışmada, koronavirüs hastalığı 2019 [coronavirus diseases-2019 (COVID-19)] hastalarının serum IDO-1 düzeyleri, Th1-2- 17 ile ilişkili sitokinlerin düzeyleri ve hematolojik parametreler, hastalığın şiddeti (hafif, orta, şiddetli) göz önünde bulundurularak araştırılması amaçlanmıştır. Yüz otuz hasta ve 91 sağlıklı kontrol için IDO1 serum seviyeleri enzim ilişkili immünsorban assay [enzyme linked immunosorbant assay (ELISA)] yöntemi kullanılarak ölçülmüş ve karşılaştırılmıştır. IDO gen lokusundaki daha önce enflamasyonla ilişkilendirilmiş olan tek nükleotit polimorfizm [single nucleotid polymorphism (SNP)] bölgesi taranmıştır. SNP analizleri, erime eğrisi (melting curve) analiziyle gerçekleştirilmiştir. Kırk COVID-19 hastasının IDO-1 intronik varyant rs7820268 ve IDO-2 inaktivitesinden sorumlu rs4503083 SNP bölgeleri, elli iki sağlıklı kontrol ile karşılaştırmalı olarak incelenmiştir. Tüm sonuçlar istatistiksel olarak analiz edilmiş ve karşılaştırılmıştır. IDO-1 serum konsantrasyonları hasta grubunda sağlıklı kontrol grubuna göre anlamlı olarak düşük bulunmuştur (p< 0.0001). Ayrıca, şiddetli hasta grubundaki IDO-1 serum seviyeleri, hafif hasta grubundan daha düşük olarak belirlenmiştir (p= 0.026). Hasta grubunda IL-4, IL-6, IL-10, TNF-α serum seviyeleri anlamlı derecede yüksek bulunurken, IFN-γ seviyeleri düşük olarak tespit edilmiştir. IDO1 ve IL-6 seviyeleri arasında ise negatif bir korelasyon bulunmuştur (r= -0.3503, p= 0.0391). Hastalık şiddetine göre sınıflandırılan hasta gruplarında lenfosit, monosit, nötrofil ve akut faz reaktan değerleri karşılaştırıldığında anlamlı farklılıklar bulunmuştur. SNP analizi sonucunda, rs7820268 IDO-1 bölgesi için CC genotipi COVID-19 hasta grubunda sağlıklı kontrol grubuna göre önemli ölçüde daha yüksek bulunmuştur (p= 0.0017). Bu veriler, IDO-1 rs7820268 SNP bölgesindeki polimorfizmin COVID-19'a duyarlılıkla ilişkili olabileceğini düşündürmektedir.
- 21 October 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (5) , 2274-2284
Interleukin-21: a potential biomarker for diagnosis and predicting prognosis in COVID-19 patients
Interleukin-21: A Potential Biomarker For Diagnosis and Predicting Prognosis in COVID-19 Patients Abstract Introduction COVID-19 patients have a wide spectrum of disease severity. Several biomarkers were evaluated as predictors for progression towards severe disease. IL-21 is a member of common ?-chain cytokine family and creates some specific effects during programming and maintenance of antiviral immunity. We aimed to assess IL-21 as a biomarker for diagnosis and outcome prediction in patients hospitalized with COVID-19. Method Patients with a preliminary diagnosis of COVID-19 and pneumonia other than COVID-19 admitted to a tertiary care hospital were included consecutively in this comparative study. Results The study population consisted of 51 patients with COVID-19 and 11 patients with non-COVID-19 pneumonia. Serum IL-21 concentration was markedly higher and serum CRP concentration was significantly lower in COVID-19 patients compared to non-COVID-19 pneumonia patients. Within COVID-19 patients 10 patients showed radiological and clinical progression. Patients with clinical worsening had lower lymphocyte count and haemoglobin. In addition to that deteriorating patients had higher urea, LDH levels and elevated concentration of both IL-6 and IL-21. The cut-off value of 106 ng/L for IL-21 has 80.0% sensitivity, %60.9 specificity for discriminating patients with clinical worsening. Multivariable analysis performed to define risk factors for disease progression identified IL-6 and IL-21 as independent predictors. Odds ratio for serum IL-6 concentrations ? 3.2 pg/mL was 8.07 (95% CI: 1.37-47.50, p=0.04) and odds ratio for serum IL-21 concentrations ? 106 ng/L was 6.24 (95% CI: 1.04 ? 37.3, p=0.02). Conclusion We identified specific differences in serum IL-21 between COVID-19 and non-COVID-19 pneumonia patients. Serum IL-21 measurement has promising predictive value for disease progression in COVID-19 patients. High serum IL-6 and IL-21 levels obtained upon admission are independent risk factors for clinical worsening.
- 21 October 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (5) , 2274-2284
Interleukin-21: a potential biomarker for diagnosis and predicting prognosis in COVID-19 patients
Interleukin-21: A Potential Biomarker For Diagnosis and Predicting Prognosis in COVID-19 Patients Abstract Introduction COVID-19 patients have a wide spectrum of disease severity. Several biomarkers were evaluated as predictors for progression towards severe disease. IL-21 is a member of common ?-chain cytokine family and creates some specific effects during programming and maintenance of antiviral immunity. We aimed to assess IL-21 as a biomarker for diagnosis and outcome prediction in patients hospitalized with COVID-19. Method Patients with a preliminary diagnosis of COVID-19 and pneumonia other than COVID-19 admitted to a tertiary care hospital were included consecutively in this comparative study. Results The study population consisted of 51 patients with COVID-19 and 11 patients with non-COVID-19 pneumonia. Serum IL-21 concentration was markedly higher and serum CRP concentration was significantly lower in COVID-19 patients compared to non-COVID-19 pneumonia patients. Within COVID-19 patients 10 patients showed radiological and clinical progression. Patients with clinical worsening had lower lymphocyte count and haemoglobin. In addition to that deteriorating patients had higher urea, LDH levels and elevated concentration of both IL-6 and IL-21. The cut-off value of 106 ng/L for IL-21 has 80.0% sensitivity, %60.9 specificity for discriminating patients with clinical worsening. Multivariable analysis performed to define risk factors for disease progression identified IL-6 and IL-21 as independent predictors. Odds ratio for serum IL-6 concentrations ? 3.2 pg/mL was 8.07 (95% CI: 1.37-47.50, p=0.04) and odds ratio for serum IL-21 concentrations ? 106 ng/L was 6.24 (95% CI: 1.04 ? 37.3, p=0.02). Conclusion We identified specific differences in serum IL-21 between COVID-19 and non-COVID-19 pneumonia patients. Serum IL-21 measurement has promising predictive value for disease progression in COVID-19 patients. High serum IL-6 and IL-21 levels obtained upon admission are independent risk factors for clinical worsening.